KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBITDA Margin (2017 - 2025)

Sarepta Therapeutics has reported EBITDA Margin over the past 12 years, most recently at 92.92% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 11748.0% year-over-year to 92.92%; the TTM value through Dec 2025 reached 31.61%, down 4419.0%, while the annual FY2025 figure was 31.83%, 4330.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 92.92% at Sarepta Therapeutics, down from 44.99% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 32.21% in Q2 2025 and troughed at 2342.69% in Q1 2023.
  • A 5-year average of 253.89% and a median of 42.66% in 2025 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: crashed -229274bps in 2023 and later surged 235104bps in 2024.
  • Year by year, EBITDA Margin stood at 60.55% in 2021, then surged by 77bps to 13.86% in 2022, then surged by 132bps to 4.38% in 2023, then skyrocketed by 461bps to 24.56% in 2024, then plummeted by -478bps to 92.92% in 2025.
  • Business Quant data shows EBITDA Margin for SRPT at 92.92% in Q4 2025, 44.99% in Q3 2025, and 32.21% in Q2 2025.